MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings DSO Ratio 2011-2026 | ONVO
Annual DSO Ratio Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.8 | 310 | - | - | 18.4 | 65.9 | 81.5 | 55.8 | 63.7 | - | - | 166 | 49.4 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 310 | 18.4 | 98.9 |
Quarterly DSO Ratio Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114 | 104 | 76.5 | - | 105 | 117 | 94.8 | - | 803 | - | 183 | - | 26.5 | - | - | - | - | - | - | - | - | - | - | - | 120 | 177 | 38.6 | 71.7 | 59.9 | 64.6 | 73.1 | 84.9 | 121 | 87 | 68.6 | 94.2 | 107 | 13.5 | 9.73 | 21.7 | 53.7 | 20.7 | 15.2 | - | 9.85 | 29.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 803 | 9.73 | 98.8 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
82.1 | $ 9.26 | 1.09 % | $ 617 M |  USA |
|
Biodesix
BDSX
|
41.7 | $ 14.6 | -3.63 % | $ 1.89 B | USA |
 |
DarioHealth Corp.
DRIO
|
56.7 | $ 8.45 | 9.74 % | $ 33.7 M |  Israel |
 |
DexCom
DXCM
|
87 | $ 66.09 | -1.12 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 103.08 | 3.09 % | $ 8.5 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
43.5 | $ 573.29 | -0.42 % | $ 46.1 B | USA |
 |
Illumina
ILMN
|
61.3 | $ 124.4 | -1.43 % | $ 19.8 B | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
50.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
101 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 466.6 | -0.04 % | $ 13.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.62 | -1.28 % | $ 428 M | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.52 | 1.98 % | $ 392 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Natera
NTRA
|
81.5 | $ 196.15 | -0.62 % | $ 19.3 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 165.13 | -0.46 % | $ 8.18 B | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
240 | $ 1.17 | -1.68 % | $ 812 M | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.35 | -2.88 % | $ 405 M | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 4.59 | 22.4 % | $ 2.46 M | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 7.32 | -4.94 % | $ 434 M | USA |
 |
Interpace Biosciences
IDXG
|
53.1 | $ 1.73 | 2.37 % | $ 7.59 M | USA |
 |
RadNet
RDNT
|
34.5 | $ 59.41 | -2.06 % | $ 4.47 B | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Senseonics Holdings
SENS
|
10.3 | $ 6.56 | -2.96 % | $ 274 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 268.38 | 0.89 % | $ 22.3 B | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 7.76 | -0.13 % | $ 994 M | USA |
 |
Soleno Therapeutics
SLNO
|
27 | $ 31.83 | -0.03 % | $ 1.62 B | USA |
 |
Psychemedics Corporation
PMD
|
61.3 | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
28.1 | $ 27.2 | -0.15 % | $ 35.3 M | USA |